Blood Advances
Công bố khoa học tiêu biểu
* Dữ liệu chỉ mang tính chất tham khảo
Sắp xếp:
Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin diseaseKey Points This is the first study to compare thromboembolism and mortality risk in CAD against a general population cohort. Patients with CAD were at a significantly increased risk of death, especially during the first 5 years after diagnosis.
Blood Advances - Tập 3 - Trang 2980-2985 - 2019
Fundamentals of immunology for understanding immunotherapy for lymphomaAbstract
An effective antitumor immune response in patients with lymphoma would eradicate the malignant B cells and cure the patient of the disease. This, however, does not occur, and a suboptimal antitumor response results in persistence and subsequent progression of the patient’s disease. The goals of immunotherapy are therefore to restore an effec... ... hiện toàn bộ
Blood Advances - Tập 4 - Trang 5863-5867 - 2020
Thromboembolic events, bleeding, and mortality in patients with cerebral venous thrombosis: a nationwide cohort studyAbstract
Cerebral venous thrombosis (CVT) predominantly affects young to middle-aged women. Scarce data exist regarding the long-term prognosis. We examined the clinical course of patients with CVT overall and according to their age and sex. Using Danish registries, we identified all patients with a first-time primary inpatient diagnosis of CVT from ... ... hiện toàn bộ
Blood Advances - Tập 7 - Trang 2070-2081 - 2023
Association of race and ethnicity with clinical phenotype, genetics, and survival in pediatric acute myeloid leukemiaAbstract
Black and Hispanic children with acute myeloid leukemia (AML) have worse outcomes compared with White children. AML is a heterogeneous disease with numerous genetic subtypes in which these disparities have not been specifically investigated. In this study, we used the Therapeutically Applicable Research to Generate Effective Treatments (TARG... ... hiện toàn bộ
Blood Advances - Tập 5 - Trang 4992-5001 - 2021
Hypoxia-inducible KDM3A addiction in multiple myelomaKey Points
Under hypoxia, KDM3A, but not IRF4, leads myeloma cells to acquire an antiapoptotic phenotype. KDM3A regulates a long noncoding RNA, MALAT1, leading to upregulation of glycolytic genes under hypoxia.
Blood Advances - Tập 2 - Trang 323-334 - 2018
ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphomaAbstract
Approximately 90% of limited-stage Hodgkin lymphoma (HL) patients are projected to be cured with standard therapy, but many do not live their expected life span because of late treatment–related complications. New treatment paradigms are needed to reduce the use of radiation therapy (RT) as well as conventional chemotherapy drugs while impro... ... hiện toàn bộ
Blood Advances - Tập 4 - Trang 2548-2555 - 2020
Post–hematopoietic stem cell transplantation immune-mediated anemia: a literature review and novel therapeuticsAbstract Anemia after allogeneic hematopoietic stem cell transplantation (HSCT) can be immune or non–immune mediated. Auto- or alloimmunity resulting from blood group incompatibility remains an important cause in post-HSCT immune-mediated anemia. ABO incompatibility is commonly encountered in HSCT and may lead to serious clinical complications, including acute hemol... ... hiện toàn bộ
Blood Advances - Tập 6 - Trang 2707-2721 - 2022
Updated international consensus report on the investigation and management of primary immune thrombocytopeniaAbstract Over the last decade, there have been numerous developments and changes in treatment practices for the management of patients with immune thrombocytopenia (ITP). This article is an update of the International Consensus Report published in 2010. A critical review was performed to identify all relevant articles published between 2009 and 2018. An expert panel... ... hiện toàn bộ
Blood Advances - Tập 3 - Trang 3780-3817 - 2019
CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparisonAbstract
CD19-directed chimeric antigen receptor (CAR) T-cell treatment has evolved as standard of care (SOC) for multiply relapsed/refractory (R/R) large B-cell lymphoma (LBCL). However, its potential benefit over allogeneic hematopoietic cell transplantation (alloHCT) remains unclear. We compared outcomes with both types of cellular immunotherapy (... ... hiện toàn bộ
Blood Advances - Tập 4 - Trang 6157-6168 - 2020
Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC studyAbstract
Alemtuzumab (anti-CD52 antibody) is frequently prescribed to children with nonmalignant diseases undergoing allogeneic hematopoietic stem cell transplantation (HSCT) to prevent graft failure (GF) and acute graft-versus-host disease (aGVHD). The aim of this multicenter study was the characterization of alemtuzumab population pharmacokinetics ... ... hiện toàn bộ
Blood Advances - Tập 7 - Trang 4462-4474 - 2023
Tổng số: 1,527
- 1
- 2
- 3
- 4
- 5
- 6
- 10